| Read Time: < 1 minute | news

Taxotere Approved for Use to Treat Type of Prostate Cancer

May 2004 – Taxotere was approved for use in combination with prednisone for the treatment of metastatic, androgen-independent prostate cancer. Reference: Martins, Ines. “Docetaxel.” Prostate Cancer News Today, 11 Mar. 2016, prostatecancernewstoday.com/docetaxel/

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved for Use as Injection

December 1999 – Taxotere was approved as an injection to treat patients suffering from locally advanced or metastatic non-small cell lung cancer following failure of prior platinum-based chemotherapy. Reference: “FDA Approves New Taxotere® (Docetaxel) Injection Concentrate Formulation – Aug 5, 2010.” Sanofi, www.news.sanofi.us/press-releases?item=118530

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved for Treatment of Metastatic Breast Cancer

June 1998 – Taxotere was approved for first-line treatment of metastatic breast cancer in subjects whose disease had recurred despite adjuvant therapy. Reference: “Taxotere (Docetaxel).” CenterWatch RSS, www.centerwatch.com/directories/1067-fda-approved-drugs/listing/4266-taxotere-docetaxel

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

GlaxoKlineSmith Ranitidine Patent Expires

1997 — In 1997, GlaxoKlineSmith’s U.S. patent for ranitidine expired.  Competitors were now able to create generic alternatives. Reference:  “Timeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.” Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved by FDA

May 1996 – Taxotere was approved for use by the U.S. Food & Drug Administration. Reference: “Taxotere Gets FDA Approval for Treatment of Advanced Breast Cancer.” Cancer Network, www.cancernetwork.com/view/taxotere-gets-fda-approval-treatment-advanced-breast-cancer

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Zantac Experiences Exponential Growth

1988 — In 1988, Zantac became the world’s best selling drug and one of the first drugs to ever top $1 billion in annual sales. Reference:  “Timeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.” Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Zantac Approved by FDA

1983 — Zantac was first approved by the FDA and sold in the U.S. in 1983. Reference:  “Timeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.” Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading

| Read Time: < 1 minute | Defective Consumer Devices

Roundup Hits The Market

1974 — Monsanto’s glyphosate-based herbicide Roundup hit the market in 1974. Reference:  Moncivais, Katy. “Roundup Cancer Lawsuit: 2020 Updates & Settlements.” Consumer Safety, 8 Jan. 2021, www.consumersafety.org/product-lawsuits/roundup/.

Continue Reading

| Read Time: < 1 minute | Defective Consumer Devices

Monsanto Develops Roundup

1970 — Monsanto developed glyphosate as an herbicide in 1970.  The company patented glyphosate as a weed killer in 1970 and kept the patent until 2000. Reference:  Moncivais, Katy. “Roundup Cancer Lawsuit: 2020 Updates & Settlements.” Consumer Safety, 8 Jan. 2021, www.consumersafety.org/product-lawsuits/roundup/.

Continue Reading